1
|
Hempel S, Danz M, Robinson KA, Bolshakova M, Rodriguez J, Mears A, Pham C, Yagyu S, Motala A, Tolentino D, Akbari O, Johnston J. Multiple chemical sensitivity scoping review protocol: overview of research and MCS construct. BMJ Open 2023; 13:e072098. [PMID: 37739463 PMCID: PMC10533706 DOI: 10.1136/bmjopen-2023-072098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 08/16/2023] [Indexed: 09/24/2023] Open
Abstract
INTRODUCTION Multiple chemical sensitivity (MCS) has been characterised by reported adverse responses to environmental exposures of common chemical agents (eg, perfumes, paint, cleaning products and other inhaled or ingested agents) in low doses considered non-toxic for the general population. There is currently no consensus on whether MCS can be established as a distinct disorder. METHODS AND ANALYSIS The scoping review of the literature will be guided by five questions: How is MCS defined and which diagnostic criteria have been proposed? What methods are used to report prevalence and incidence estimates of MCS? What are the characteristics of the body of scientific evidence that addresses whether MCS is a distinct disorder or syndrome? What underlying mechanisms for MCS have been proposed in the scientific literature? Which treatment and management approaches for MCS have been evaluated in empirical research studies? We will conduct a comprehensive search in 14 research databases. Citation screening will be supported by machine learning algorithms. Two independent reviewers will assess eligibility of full-text publications against prespecified criteria. Data abstraction will support concise evidence tables. A formal consultation exercise will elicit input regarding the review results and presentation. The existing research evidence will be documented in a user-friendly visualisation in the format of an evidence map. ETHICS AND DISSEMINATION Determined to be exempt from review (UP-22-00516). Results will be disseminated through a journal manuscript and data will be publicly accessible through an online data repository. REGISTRATION DETAILS The protocol is registered in Open Science Framework (osf.io/4a3wu).
Collapse
Affiliation(s)
- Susanne Hempel
- Southern California Evidence Review Center, University of Southern California, Los Angeles, California, USA
| | - Margie Danz
- Southern California Evidence Review Center, University of Southern California, Los Angeles, California, USA
| | - Karen A Robinson
- Division of Health Science Informatics, John Hopkins Medicine, Baltimore, Maryland, USA
| | - Maria Bolshakova
- Southern California Evidence Review Center, University of Southern California, Los Angeles, California, USA
| | - Jesus Rodriguez
- Southern California Evidence Review Center, University of Southern California, Los Angeles, California, USA
| | - Alanna Mears
- Southern California Evidence Review Center, University of Southern California, Los Angeles, California, USA
| | - Cindy Pham
- Southern California Evidence Review Center, University of Southern California, Los Angeles, California, USA
| | - Sachi Yagyu
- Southern California Evidence Review Center, University of Southern California, Los Angeles, California, USA
| | - Aneesa Motala
- Southern California Evidence Review Center, University of Southern California, Los Angeles, California, USA
| | - Danica Tolentino
- Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Omid Akbari
- Molecular Microbiology and Immunology, University of Southern California, Los Angeles, California, USA
| | - Jill Johnston
- Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| |
Collapse
|
2
|
Huang J, Santos AC, Tan Q, Bai H, Hu X, Mamidi N, Wu Z. Black phosphorous-based biomaterials for bone defect regeneration: a systematic review and meta-analysis. J Nanobiotechnology 2022; 20:522. [PMID: 36496422 PMCID: PMC9741806 DOI: 10.1186/s12951-022-01735-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2022] [Accepted: 12/01/2022] [Indexed: 12/13/2022] Open
Abstract
Critical-sized bone defects are always difficult to treat, and they are associated with a significant burden of disease in clinical practice. In recent decades, due to the fast development of biomaterials and tissue engineering, many bioinspired materials have been developed to treat large bone defects. Due to the excellent osteoblastic ability of black phosphorous (BP), many BP-based biomaterials have been developed to treat bone defects. Therefore, there are abundant studies as well as a tremendous amount of research data. It is urgent to conduct evidence-based research to translate these research data and results into validated scientific evidence. Therefore, in our present study, a qualitative systematic review and a quantitative meta-analysis were performed. Eighteen studies were included in a systematic review, while twelve studies were included in the meta-analysis. Our results showed that the overall quality of experimental methods and reports of biomaterials studies was still low, which needs to be improved in future studies. Besides, we also proved the excellent osteoblastic ability of BP-based biomaterials. But we did not find a significant effect of near-infrared (NIR) laser in BP-based biomaterials for treating bone defects. However, the quality of the evidence presented by included studies was very low. Therefore, to accelerate the clinical translation of BP-based biomaterials, it is urgent to improve the quality of the study method and reporting in future animal studies. More evidence-based studies should be conducted to enhance the quality and clinical translation of BP-based biomaterials.
Collapse
Affiliation(s)
- Jinfeng Huang
- grid.233520.50000 0004 1761 4404Department of Orthopaedics, Xijing Hospital, The Air Force Medical University, Xi’an, 710032 Shaanxi People’s Republic of China
| | - Ana Cláudia Santos
- grid.8051.c0000 0000 9511 4342Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal ,grid.8051.c0000 0000 9511 4342REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal
| | - Quanchang Tan
- grid.233520.50000 0004 1761 4404Department of Orthopaedics, Xijing Hospital, The Air Force Medical University, Xi’an, 710032 Shaanxi People’s Republic of China
| | - Hao Bai
- grid.233520.50000 0004 1761 4404Department of Orthopaedics, Xijing Hospital, The Air Force Medical University, Xi’an, 710032 Shaanxi People’s Republic of China
| | - Xiaofan Hu
- grid.233520.50000 0004 1761 4404Department of Orthopaedics, Xijing Hospital, The Air Force Medical University, Xi’an, 710032 Shaanxi People’s Republic of China
| | - Narsimha Mamidi
- grid.419886.a0000 0001 2203 4701Department of Chemistry and Nanotechnology, School of Engineering and Science, Tecnologico de Monterrey, 64849 Monterrey, NL Mexico
| | - Zixiang Wu
- grid.233520.50000 0004 1761 4404Department of Orthopaedics, Xijing Hospital, The Air Force Medical University, Xi’an, 710032 Shaanxi People’s Republic of China
| |
Collapse
|
3
|
Kelly C, Fitzpatrick P, Quinn C, Flanagan F, Connors A, Larke A, Mooney T, Kennedy M, Sheehan M, Bennett MW, Brodie C, O'Doherty A. Screen-detected ductal carcinoma in situ, 2008-2020: An observational study. J Med Screen 2022; 29:172-177. [PMID: 35341364 DOI: 10.1177/09691413221090739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVES The purpose of this study was to evaluate the grade distribution of screen-detected ductal carcinoma in situ (DCIS) diagnosed in Ireland, in the context of the clinical trials currently underway to determine if active surveillance is a feasible management option for low-risk DCIS. SETTING BreastCheck is the national breast screening programme in Ireland, offering screening to women aged 50 to 69 every two years. METHODS This study was a secondary analysis of data collected by BreastCheck on all screen-detected DCIS diagnosed in the 12 years of nationwide screening. Incidence and detection rates were calculated. Descriptive analysis of the cases was performed and, for comparative analysis, grade of DCIS was analysed as a binary variable (high vs. low/intermediate) in keeping with the inclusion criteria for active surveillance trials. Analysis was performed in IBM Statistical Package for Social Sciences, version 26. RESULTS Between 2008 and 2020, 2240 women were diagnosed with DCIS through BreastCheck; 876 (39.1%) were low/intermediate-grade. The overall incidence rate has remained relatively stable during this period. Women with low/intermediate-grade DCIS were younger than women with high-grade DCIS (56 (interquartile range: 56-61) years v 57 (interquartile range: 53-61) years; p < 0.001). They were also more likely to have been diagnosed at an initial screening episode compared with those who had high-grade lesions (42.5% v 29.0%; p < 0.001). CONCLUSION If current clinical trials recommend active surveillance as a feasible option for DCIS, up to 40% of women with screen-detected DCIS may be eligible. These women are younger and often diagnosed on initial screening episode, so may require longer active follow-up.
Collapse
Affiliation(s)
- Caitriona Kelly
- School of Public Health, Physiotherapy and Sports Science, 8797University College Dublin, Dublin, Ireland.,Department of Public Health HSE North East, Navan, Ireland
| | - Patricia Fitzpatrick
- School of Public Health, Physiotherapy and Sports Science, 8797University College Dublin, Dublin, Ireland.,155307National Screening Service, Dublin, Ireland
| | - Cecily Quinn
- BreastCheck, 155307National Screening Service, Dublin, Ireland
| | | | - Alissa Connors
- BreastCheck, 155307National Screening Service, Dublin, Ireland
| | - Aideen Larke
- BreastCheck, 155307National Screening Service, Dublin, Ireland
| | | | - Maria Kennedy
- BreastCheck, 155307National Screening Service, Dublin, Ireland
| | | | - Michael W Bennett
- 155307National Screening Service, Dublin, Ireland.,Department of Pathology, 57983Cork University Hospital, Cork, Ireland
| | - Caroline Brodie
- BreastCheck, 155307National Screening Service, Dublin, Ireland.,Department of Anatomic Pathology, 58040Galway University Hospital and National University of Ireland, Galway, Ireland
| | - Ann O'Doherty
- BreastCheck, 155307National Screening Service, Dublin, Ireland
| |
Collapse
|